Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
Emergent BioSolutions (NYSE: EBS) is expanding access to NARCAN® Nasal Spray, the first FDA-approved over-the-counter 4 mg naloxone product for opioid overdose emergency treatment. The initiative comes as opioid overdose deaths show their first decline in five years nationwide.
The company is launching two key partnerships:
- Collaboration with NYC Building & Construction Industry Safety Fund to implement HOPE/LIVES program, providing training and emergency kits with two doses of NARCAN® to construction workers, who face higher opioid prescription rates and fatal overdose risks
- Partnership with Pathway Healthcare to supply NARCAN® Nasal Spray across their Mississippi locations, enhancing accessibility in addiction treatment and mental health facilities
These initiatives aim to increase opioid emergency preparedness and reduce barriers to access, while providing education on overdose recognition and proper administration of the life-saving medication.
Emergent BioSolutions (NYSE: EBS) sta ampliando l'accesso al NARCAN® Nasal Spray, il primo prodotto di naloxone da 4 mg approvato dalla FDA per il trattamento di emergenza in caso di overdose da oppioidi. Questa iniziativa arriva mentre i decessi per overdose da oppioidi mostrano il loro primo calo in cinque anni a livello nazionale.
La compagnia sta lanciando due importanti collaborazioni:
- Collaborazione con il NYC Building & Construction Industry Safety Fund per implementare il programma HOPE/LIVES, fornendo formazione e kit di emergenza con due dosi di NARCAN® ai lavoratori edili, che affrontano tassi più elevati di prescrizioni di oppioidi e rischi di overdose fatali.
- Partnership con Pathway Healthcare per fornire NARCAN® Nasal Spray nelle loro sedi del Mississippi, migliorando l'accessibilità nei centri di trattamento per la dipendenza e nelle strutture di salute mentale.
Queste iniziative mirano ad aumentare la preparazione per le emergenze legate agli oppioidi e a ridurre le barriere all'accesso, fornendo al contempo istruzioni sul riconoscimento dell'overdose e sulla corretta somministrazione del farmaco salvavita.
Emergent BioSolutions (NYSE: EBS) está ampliando el acceso al NARCAN® Nasal Spray, el primer producto de naloxona de 4 mg aprobado por la FDA para el tratamiento de emergencia en casos de sobredosis de opioides. Esta iniciativa surge mientras que las muertes por sobredosis de opioides muestran su primera disminución en cinco años a nivel nacional.
La compañía está lanzando dos asociaciones clave:
- Colaboración con el NYC Building & Construction Industry Safety Fund para implementar el programa HOPE/LIVES, proporcionando capacitación y kits de emergencia con dos dosis de NARCAN® a los trabajadores de la construcción, quienes enfrentan tasas más altas de prescripción de opioides y riesgos de sobredosis fatales.
- Asociación con Pathway Healthcare para suministrar NARCAN® Nasal Spray en sus ubicaciones de Mississippi, mejorando la accesibilidad en centros de tratamiento de adicciones y en instalaciones de salud mental.
Estas iniciativas tienen como objetivo aumentar la preparación para emergencias relacionadas con opioides y reducir las barreras de acceso, al mismo tiempo que se proporciona educación sobre el reconocimiento de sobredosis y la correcta administración del medicamento que salva vidas.
Emergent BioSolutions (NYSE: EBS)는 오피오이드 과다복용 응급 치료를 위한 FDA 승인 4 mg 날록손 제품인 NARCAN® Nasal Spray에 대한 접근성을 확대하고 있습니다. 이 이니셔티브는 오피오이드 과다복용 사망자가 5년 만에 처음으로 감소하고 있는 가운데 진행됩니다.
회사는 두 가지 주요 파트너십을 시작하고 있습니다:
- NYC 건설 산업 안전 기금과 협력하여 HOPE/LIVES 프로그램을 시행하고, 건설 근로자에게 두 도즈의 NARCAN®이 포함된 응급 키트와 교육을 제공합니다. 이들은 높은 오피오이드 처방 비율과 치명적인 과다복용 위험에 직면해 있습니다.
- Pathway Healthcare와의 파트너십을 통해 미시시피 지역에서 NARCAN® Nasal Spray를 공급하여 중독 치료 및 정신 건강 시설의 접근성을 향상시킵니다.
이러한 이니셔티브는 오피오이드 응급 대비를 강화하고 접근 장벽을 줄이는 동시에, 과다복용 인식 및 생명을 구하는 약물의 올바른 사용법에 대한 교육을 제공합니다.
Emergent BioSolutions (NYSE: EBS) élargit l'accès au NARCAN® Nasal Spray, le premier produit de naloxone de 4 mg approuvé en vente libre par la FDA pour le traitement d'urgence des overdoses aux opioïdes. Cette initiative intervient alors que les décès par overdose aux opioïdes montrent leur première baisse en cinq ans à l'échelle nationale.
L'entreprise lance deux partenariats clés :
- Collaboration avec le NYC Building & Construction Industry Safety Fund pour mettre en œuvre le programme HOPE/LIVES, fournissant une formation et des kits d'urgence contenant deux doses de NARCAN® aux travailleurs de la construction, qui sont confrontés à des taux de prescription d'opioïdes plus élevés et à des risques d'overdose mortels.
- Partenariat avec Pathway Healthcare pour fournir le NARCAN® Nasal Spray dans leurs établissements du Mississippi, améliorant ainsi l'accessibilité dans les centres de traitement des dépendances et les établissements de santé mentale.
Ces initiatives visent à renforcer la préparation aux urgences liées aux opioïdes et à réduire les barrières d'accès, tout en fournissant des informations sur la reconnaissance des overdoses et l'administration correcte du médicament salvateur.
Emergent BioSolutions (NYSE: EBS) erweitert den Zugang zu NARCAN® Nasal Spray, dem ersten FDA-zugelassenen rezeptfreien Naloxon-Produkt mit 4 mg zur Notfallbehandlung von Opioidüberdosierungen. Diese Initiative erfolgt, da die Todesfälle durch Opioidüberdosierungen landesweit erstmals seit fünf Jahren zurückgehen.
Das Unternehmen startet zwei wichtige Partnerschaften:
- Zusammenarbeit mit dem NYC Building & Construction Industry Safety Fund zur Umsetzung des HOPE/LIVES-Programms, das Schulungen und Notfallkits mit zwei Dosen NARCAN® für Bauarbeiter bereitstellt, die höheren Opioidverschreibungsraten und tödlichen Überdosierungsrisiken ausgesetzt sind.
- Partnerschaft mit Pathway Healthcare zur Bereitstellung von NARCAN® Nasal Spray an ihren Standorten in Mississippi, um die Zugänglichkeit in Suchtbehandlungs- und psychiatrischen Einrichtungen zu verbessern.
Diese Initiativen zielen darauf ab, die Notfallbereitschaft bei Opioiden zu erhöhen und Zugangsbarrieren abzubauen, während gleichzeitig Schulungen zur Erkennung von Überdosierungen und zur richtigen Anwendung des lebenserhaltenden Medikaments angeboten werden.
- FDA-approved OTC status for NARCAN® expands market accessibility
- Strategic partnerships with construction industry and healthcare providers increase product distribution
- First decline in opioid deaths in 5 years validates product demand and market strategy
- High dependence on specific market segments (construction, healthcare) for distribution
- Competitive pressure may increase with OTC status allowing more market entries
- NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and provide trainings on how to administer the life-saving medicine
- Leading mental health and addiction treatment services provider, Pathway Healthcare, breaks down stigma and access barriers by making NARCAN® Nasal Spray available in all Mississippi locations
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread opioid emergency preparedness as opioid overdose death rates continue to decline nationwide for the first time in five years.1 These efforts include working with organizations to expand access to NARCAN® Nasal Spray and educate the public on how to respond to an opioid overdose emergency.
NARCAN® Nasal Spray is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. Despite the recent progress made in stemming the tide of the opioid epidemic, overdose risks persist, especially within the construction industry. Recognizing that construction workers are more likely to be prescribed opioids2 and have the highest rate of fatal drug overdoses compared to other occupations3, Emergent is supporting the NYC Building & Construction Industry Safety Fund in the launch of their new educational program, HOPE/LIVES. As part of HOPE/LIVES, trainings at jobsites will educate workers on the signs of an opioid overdose and how to administer NARCAN® Nasal Spray in an opioid emergency. Every worker will also receive an opioid emergency kit with two doses of the life-saving medication, so they can be prepared to save a life when every minute counts.
Emergent is dedicated to ensuring addiction treatment and mental health providers have the tools they need to make an impact on the frontlines of the epidemic. That’s why Emergent is also working with Pathway Healthcare to equip its network of Mississippi locations with NARCAN® Nasal Spray. Having the treatment more readily available in their offices is an important safety precaution for patients and their families impacted by opioid use disorder that will ultimately help save lives.
“Access to naloxone can mean the difference between life and death in an opioid overdose emergency,” said Dr. Stephen Taylor, Chief Medical Officer of Pathway Healthcare. “By ensuring that NARCAN® Nasal Spray is readily available in our clinics, we are taking a necessary step in providing immediate support to those at risk. Our goal is to make life-saving interventions as accessible as possible.”
Pathway Healthcare operates multiple locations throughout the Southeast, offering comprehensive behavioral health and substance use services. With a patient-centered approach, Pathway Healthcare strives to provide accessible and compassionate care to individuals seeking recovery and mental wellness.
“At Pathway, we are dedicated to making sure that our patients and their loved ones have access to essential resources without hesitation,” said Lindsay Lane, VP of Business Development at Pathway Healthcare. “This initiative is about more than just access – it’s about fostering a supportive environment where individuals feel empowered to seek help without fear or stigma.”
“The recent decline in opioid overdose deaths reinforces the positive impact of increased education and access to tools like naloxone nasal spray. We applaud NYC Building & Construction Industry Safety Fund and Pathway Healthcare for stepping up and doing their part to combat opioid overdose deaths,” said Paul Williams, senior vice president, products head at Emergent BioSolutions. “It takes a united front – from advocacy groups to public servants, government officials and retailers – and together, we won’t stop until every individual, business and venue is prepared to help save a life in an opioid emergency.”
Learn more about how you can access NARCAN® Nasal Spray and be prepared to save a life at NARCAN.com.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
1 U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm
2 Ompad DC, Gershon RR, Sandh S, Acosta P, Palamar JJ. Construction trade and extraction workers: A population at high risk for drug use in the United States, 2005–2014. Drug and Alcohol Dependence. 2019;205:107640. doi: https://doi.org/10.1016/j.drugalcdep.2019.107640
3The Nation’s Health. Construction Sector Struggles With Opioid Overdose Deaths. August 2024. https://www.thenationshealth.org/content/54/6/1.2. Accessed February 19, 2025.
FAQ
What is the significance of NARCAN becoming over-the-counter for EBS?
How is EBS expanding NARCAN access in the construction industry?
What is EBS's strategy for NARCAN distribution in Mississippi?
How does the recent decline in opioid deaths impact EBS's NARCAN initiative?
